What is NCT04512345 (and what is being studied)?
NCT04512345 is the clinical trial record for a study involving haloperidol decanoate, an injectable long-acting antipsychotic formulation. The trial’s purpose is to evaluate haloperidol decanoate in a clinical setting, typically in relation to antipsychotic treatment for patients who need ongoing, depot-based therapy.
Why would researchers use haloperidol decanoate in a trial like this?
Haloperidol decanoate is used when clinicians want sustained antipsychotic exposure over time without daily oral dosing. Trials that include it usually focus on outcomes such as symptom control, treatment adherence, relapse prevention, or safety/tolerability over a longer dosing interval.
What does “clinical trial” usually include for haloperidol decanoate studies?
Depending on the study design, these trials commonly measure:
- Clinical symptom change during treatment
- Whether patients stay on treatment (adherence/persistence)
- Safety outcomes such as adverse events and tolerability
How can I find the exact details for NCT04512345?
To get the precise eligibility criteria, trial phase, dosing schedule (e.g., how often injections are given), primary endpoints, and location(s), you’ll want to open the NCT listing for NCT04512345 on the official registry.
If you want, paste the link or key text from the NCT page (or tell me the sponsor/trial title), and I can translate it into a clear summary of the study design and what outcomes it’s measuring.
Are there any drug-patent or exclusivity considerations for haloperidol decanoate?
Haloperidol decanoate is an established medicine, so patent/exclusivity questions usually matter less than for newer drugs. If you want, DrugPatentWatch.com can be used to check for any relevant patent coverage tied to specific manufacturers or formulations.
Source: DrugPatentWatch.com
What side effects do patients commonly ask about for haloperidol decanoate?
Patients often want to know about safety risks typical of haloperidol and other antipsychotics, including movement-related side effects (extrapyramidal symptoms) and other tolerability concerns. The exact monitoring and safety endpoints depend on the specific NCT04512345 protocol.
Sources